| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC0893 |
| Trial ID | ChiCTR2000040018 |
| Disease | B-Cell Malignancy |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19 CAR-T cells |
| Phase | Phase1 |
| Recruitment status | Not Recruiting |
| Title | Phase the Safety and Tolerability of CD19 Universal Chimeric Antigen Receptor T Cells in Subjects with R/R CD19 positive B cell malignant tumors |
| Year | 2020 |
| Country | China |
| Company sponsor | The Affiliated Hospital of Nantong University |
| Cohort1: dose level 1 | |||||||||
|
|||||||||
| Cohort2: dose level 2 | |||||||||
|
|||||||||
| Cohort3: dose level 3 | |||||||||
|
|||||||||
| Cohort4: dose level 4 | |||||||||
|
|||||||||